← board
UPC
distress 2/10 · well-funded / low risk$3.99-2%today-67% from 52w high
Revenue
$17859M
Liquidity
$33595M
Runway
6.7 yrs
Shares 1y
0%
Price & events
-6.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-12.3%
1W
+31.3%
1M
+18.8%
3M
-2.0%
6M
+4.3%
1Y
-99.8%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $2.25M
- Volume
- 10.04K
- 52 Week Range
- $2.25 – $12.18
- Total Shares
- 563.34K
- Float Shares
- 487.25K
- Short %
- 38.12%
- % Held by Insiders
- 11.38%
- % Held by Institutions
- 4.45%
- RVOL
- 0.00x
- Beta
- 1.46
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 563,338 · 0 offerings/1y · 0 PIPEs
- 2024-12-09424B5offering
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.